
## Victor S Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8823829/publications.pdf

Version: 2024-02-01



VICTOR S LIN

#	Article	IF	CITATIONS
1	Clonal hematopoiesis, myeloid disorders and <i>BAX</i> -mutated myelopoiesis in patients receiving venetoclax for CLL. Blood, 2022, 139, 1198-1207.	1.4	34
2	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Advances, 2021, 5, 4054-4058.	5.2	39
3	BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic. Cancers, 2020, 12, 3353.	3.7	12
4	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Advances, 2020, 4, 165-173.	5.2	34
5	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood, 2020, 135, 2266-2270.	1.4	67
6	Venetoclax for the treatment of mantle cell lymphoma. Annals of Lymphoma, 2019, 3, 4-4.	4.5	1